Venous thromboembolism during pregnancy, postpartum or during contraceptive use

Summary

Venous thromboembolism (VTE) is a leading cause of maternal death during pregnancy or postpartum, and in women using hormonal contraceptives. However, important issues concerning its natural history and therapy remain unsolved, and most of the protocols for treatment of VTE in this patient population are based on data extrapolated from other populations. RIETE is an ongoing registry of consecutive patients with objectively confirmed, symptomatic, acute VTE. We examined the clinical characteristics and three-month outcome of all enrolled women with pregnancy, postpartum or using hormonal contraceptives. As of December 2008, 173 pregnant women, 135 postpartum, and 798 contraceptive users were enrolled. Of these, 438 (40%) presented with pulmonary embolism (PE) and 668 with deep-vein thrombosis (DVT). Most women with acute PE had dyspnea (72%) or chest pain (75%), but only 2.0% had hypoxaemia. During the three-month study period, five women (0.45%; 95% CI: 0.17–1.00) died (3 had fatal PE), 13 (1.18%; 95% CI: 0.66–1.95) had VTE recurrences, and seven (0.63%; 95% CI: 0.28–1.25) major bleeding. Two of the three women with fatal PE died during the first few hours after arriving at the emergency ward, with no time to start any therapy. The outcome of pregnant or postpartum women with VTE is similar to that in contraceptive users, even though the treatment is different. The non-specific nature of PE signs may have caused some delay in PE diagnosis.

Keywords

Pregnancy - postpartum - contraceptives - venous thromboembolism

^* A list of the RIETE Investigators is given in the Appendix.

• References

• 1 Chang J, Elam-Evans LD, Berg CJ. et al. Pregnancy-related mortality surveillance-United States, 1991–1999. MMWR Surveill Summ 2003; 52: 1-8.
• 2 James AH. Thromboembolism in pregnancy: recurrence risks, prevention and management. Curr Opin Obstet Gynecol 2008; 20: 550-556.
• 3 Lindqvist PG, Torsson J, Almqvist A. et al. Postpartum thromboembolism: severe events might be preventable using a new risk score model. Vasc Health Risk Manag 2008; 4: 1081-1087.
• 4 Kearon C, Kahn S, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th Edition). Chest 2008; 133: 454S-545S.
• 5 Monreal M, Falgá C, Valle R. et al. for the RIETE Investigators.. Venous thromboembolism in patients with renal Insufficiency. Findings from the RIETE Registry. Am J Med 2006; 119: 1073-1079.
• 6 Blanco-Molina A, Trujillo-Santos J, Criado J. et al. for the RIETE Investigators.. Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
• 7 Blanco-Molina A, Trujillo-Santos J, Tirado R. et al. for the RIETE Investigators.. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009; 101: 478-482.
• 8 Laporte S, Mismetti P, Décousus H. et al. and the RIETE investigators. Predictive factors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism. Findings from the RIETE registry. Circulation 2008; 117: 1711-1716.
• 9 Monreal M, Falga C, Valdés M. et al. for the RIETE Investigators.. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: finding from the RIETE Registry. J Thromb Haemost 2006; 4: 1950-1956.
• 10 Nieto JA, Camara T, Gonzalez-Higueras E. et al. for the RIETE Investigators.. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 789-796.
• 11 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005; 106: 401-407.
• 12 Bauersachs RM, Dudenhausen J, Faridi A. et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245.
• 13 Bauersachs RM. Treatment of venous thromboembolism during pregnancy. Thromb Res 2009; 123 (Suppl. 02) S45-50.
• 14 Bates SM, Greer IA, Pabinger I. et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th Edition). Chest 2008; 133: 844S-886S.
• 15 Smith MP, Norris LA, Steer PJ. et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190: 495-501.
• 16 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-1029.
• 17 Rodie VA, Thomson AJ, Stewart FM. et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. Br J Obstet Gynecol 2002; 109: 1020-1024.
• 18 Parker MS, Hui FK, Camacho MA. et al. Female breast radiation exposure during CT pulmonary angiography. Am J Radiol 2005; 185: 1228-1233.
• 19 Elicker BM, Lee TJ, Webb WR. Role of multislice computed tomography of the thorax for the evaluation of suspected pulmonary embolism. Clin Pulm Med 2007; 14: 157-165.